Medicenna Therapeutics (TSE:MDNA) Shares Up 14.3% – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA) shares rose 14.3% during mid-day trading on Monday . The company traded as high as C$0.72 and last traded at C$0.72. Approximately 127,392 shares traded hands during trading, an increase of 20% from the average daily volume of 105,837 shares. The stock had previously closed at C$0.63.

Medicenna Therapeutics Trading Up 4.8%

The firm has a market capitalization of C$55.06 million, a price-to-earnings ratio of -4.40 and a beta of 2.90. The business’s 50-day moving average price is C$0.69 and its 200 day moving average price is C$0.98. The company has a debt-to-equity ratio of 3.30, a current ratio of 2.68 and a quick ratio of 4.65.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. On average, equities analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.